SB202190 (FHPI)

For research use only.

Catalog No.S1077

76 publications

SB202190 (FHPI) Chemical Structure

Molecular Weight(MW): 331.34

SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 134 In stock
USD 147 In stock
USD 370 In stock
USD 637 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's SB202190 (FHPI) has been cited by 76 publications

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Biological Activity

Description SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo.
Targets
p38α [1]
(Cell-free assay)
p38β [1]
(Cell-free assay)
50 nM 100 nM
In vitro

SB 202190 significantly inhibits both basal and anti-Fas antibody-induced MAPKAPK 2 activity in a dose-dependent manner. SB202190 by itself is sufficient to induce cell death in Jurkat and HeLa cells through activation of CPP32-like caspases, which can be blocked by expression of bcl-2. SB202190-induced apoptosis is attenuated by p38β but augmented by p38α. [2] SB 202190 strongly inhibits UVB induced COX-2 protein expression in HaCaT cells, and markedly inhibits UVB induced cox-2 mRNA. [3] SB 202190 treatment inhibits the expression of albumin-induced proinflammatory (monocyte chemoattractant protein-1) and transforming growth factor (TGF)-beta1-induced profibrotic (procollagen-Ialpha1) genes over 50% in renal tubular cells (normal rat kidney-52E). [4] SB 202190 treatment induces phosphorylation of JNK in a dose- and time- dependent manner in A549 cells, induces phosphorylation of ATF-2 transcription factor, and increases AP-1 DNA binding. [6] SB 202190 treatment enhances the growth of THP-1 and MV4-11 cells. SB 202190 increases the phosphorylation of c-Raf and ERK, suggesting that Ras-Raf-MEK-mitogen-activated protein kinase (MAPK) pathway activation is involved in the leukemia cell growth induced by SB 202190. [7]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCT-116 M3zTNGZ2dmO2aX;uJGF{e2G7 M3rVc|I2KM7:TR?= NHKyc24{OCCvaX6= NHrOTVRFVVORwrC= MXrheJRmdnWjdHXzJJRp\SCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25ib3[gbGJFNTJiaX6gdoV{eG:wc3n2[UB1dyCGQR?= NWj2T|VROjZ{MkOyOVE>
MDA-MB-231 MVjGeY5kfGmxbjDBd5NigQ>? Mm\pNkDPxE1? NWryNYJlOjRiaB?= NH3mbplt\XO|ZX7ld{BES0x{IHnu[JVkfGmxbjDifUBVVkcQsR?= NX3OcoFsOjZzMEC4OFg>
rBMSCs Mlq2SpVv[3Srb36gRZN{[Xl? NYHXW3Q2OTBizszN MlzYNk42KGh? MX7k[ZBz\XO|ZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCHUlugZY5lKHB|OB?= NEXaW28zPjB3M{K2Oi=>
MG63 MoDESpVv[3Srb36gRZN{[Xl? NUXENmpWOTBxMkCvN|Ah|ryP NHXNZ5ozPCCq NWDEN3dGe2mpbnnmbYNidnSueTDk[YNz\WG|ZYOgeIhmKGyndnXsJI9nKHCqb4PwbI9zgWyjdHXkJJA{QCCrbnT1Z4VlKGK7IFPkR4wzKGmwIHGgZ49v[2WwdILheIlwdiBvZHXw[Y5l\W62IH3hco5meg>? Mlu1NlU6QTh|MUK=
MG63 MVTBdI9xfG:|aYOgRZN{[Xl? NYGwVpJROTBxMkCvN|Ah|ryP MnO1NlQhcA>? NVy1cZlIe2mpbnnmbYNidnSueTDk[YNz\WG|ZXSgeIhmKGGyb4D0c5NqeyC{YYTlJI9nKE2JNkOgbY5lfWOnZDDifUBE\EOuMh?= MX6yOVk6QDNzMh?=
HTSMCs MWTGeY5kfGmxbjDBd5NigQ>? M1jsbVAvOS9zL{GwJO69VQ>? MmH5NUBp M1y1cYlvcGmkaYTl[EBEV1KPLUKtbY5lfWOnZDDIU{0yKHC{b4TlbY4hdGW4ZXzzJIFv\CCvUl7BJIV5eHKnc4Ppc44> MmHGNlU6OjF2NkS=
MIA PaCa-2 MVHGeY5kfGmxbjDBd5NigQ>? MljCNlDDqM7:TR?= M3fRZVI1KGh? MmTwdoVlfWOnZDDsZYN1[XSnIHHjZ5VufWyjdHnvckBqdiClb33ibY5ifGmxbjD3bZRpKGKxdHigNk1FTyCjbnSgSE1idGyxc3ZCpC=> MXyyOVg5QDR6OR?=
MIA PaCa-2 NUjUd|B3TnWwY4Tpc44hSXO|YYm= MmDoNlDDqM7:TR?= M3qzRVI1KGh? NHrXTJBz\XO3bITzJIlvKGFibX;k[ZN1KGmwaHnibZRqd25ib3[gTGlHNTIQsTDwdo91\WmwIHHjZ5VufWyjdHnvci=> MUGyOVg5QDR6OR?=
BxPC-3 NXfsZoRkTnWwY4Tpc44hSXO|YYm= NHy3fGszOMLizszN NXzpdJFjOjRiaB?= NYXnd4o2emW|dXz0d{BqdiCjIH3v[IV{fCCrbnjpZol1cW:wIH;mJGhKTi1zzsGgdJJwfGWrbjDhZ4N2dXWuYYTpc44> NGDsbYszPTh6OES4PS=>
AsPC-1 MXTGeY5kfGmxbjDBd5NigQ>? MkXNNlDDqM7:TR?= NWf6WJY6OjRiaB?= MWTy[ZN2dHS|IHnuJIEhdW:mZYP0JIlvcGmkaYTpc44hd2ZiSFnGMVHPuSCycn;0[YlvKGGlY4XteYxifGmxbh?= MlzrNlU5QDh2OEm=
MIA PaCa-2 M{[yeWZ2dmO2aX;uJGF{e2G7 M{XVNlIxyqEQvF2= Ml23NlQhcA>? M1\1[4VvcGGwY3XzJINt\WG4YXflJI9nKFCDUmCge4hmdiClb33ibY5m\CC5aYToJIdtfWOxc3WgZY5idG:pcx?= NUDvTWp1OjV6OEi0PFk>
MIA PaCa-2 NF3DdWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvuR5lYOjEEoN88US=> NWm5fmN2OiCq M2TVfZNmdnOrdHn6[ZMh[2WubDDsbY5meyC2bzD0doVifG2nboSge4l1cCB{LVTHJIFv\CCGLXHscI9{\Q>? NFfXUVUzPTh6OES4PS=>
BxPC-3 NVXj[|ROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjzbFVxOjEEoN88US=> MWmyJIg> NH:xVHR{\W6|aYTpfoV{KGOnbHygcIlv\XNidH:geJJm[XSvZX70JJdqfGhiMj3ES{BidmRiRD3hcIxwe2V? MYmyOVg5QDR6OR?=
AsPC-1 NIXVdWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfFZ3ozOMLizszN M3\seVIhcA>? MnTTd4Vve2m2aYrld{Bk\WyuIHzpcoV{KHSxIITy[YF1dWWwdDD3bZRpKDJvRFegZY5lKERvYXzsc5Nm MWCyOVg5QDR6OR?=
HEY NXnHUXlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnOyNlDDqM7:TR?= M1TpbFIhcA>? NGLwT|B{\W6|aYTpfoV{KGOnbHygcIlv\XNidH:geJJm[XSvZX70JJdqfGhiMj3ES{BidmRiRD3hcIxwe2V? MkTCNlU5QDh2OEm=
OVCAR-3 MlPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjuOnNMOjEEoN88US=> MXeyJIg> NV[5OVhbe2Wwc3n0bZpmeyClZXzsJIxqdmW|IITvJJRz\WG2bXXueEB4cXSqIEKtSGch[W6mIFStZYxtd3On M4C4ZlI2QDh6NEi5
SK-OV-3 NWLSWXpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLITnAzOMLizszN NWnnVXFGOiCq MoTZd4Vve2m2aYrld{Bk\WyuIHzpcoV{KHSxIITy[YF1dWWwdDD3bZRpKDJvRFegZY5lKERvYXzsc5Nm M37EcVI2QDh6NEi5
MH7A  MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnz2NlQhcA>? MkPtdoVqdm[xcnPld{B1cGViaX7obYJqfG:{eTDl[oZm[3S|IH;mJHhCVg>? NETSV2QzPTh4Mkm2Oi=>
MH7A  MWTBdI9xfG:|aYOgRZN{[Xl? NV;Gcng2OjVizszN MlSzNlQhcA>? MV7y[ZZmenOnczDj[YxtKGO7Y3zlJIFzemW|dDDpcoR2[2WmIHL5JHhCViCjbnSgZ4F2e2WmIHHwc5B1d3OrczDv[kBk\WyuczD2bYEh[WO2aY\heIlwdiCxZjDKUms> MYeyOVg3Ojl4Nh?=
SCC25 MXTGeY5kfGmxbjDBd5NigQ>? MYiyNEDPxE1? NV\rUHg6OjRiaB?= M1e4VIlv[3KnYYPld{BifXSxcHjh[5khdGW4ZXy= M3zjd|I2QDN2NECw
HaCaT  MoSySpVv[3Srb36gRZN{[Xl? Mnu1OUDDvU1? NU\IdXdUOjRiaB?= MYLpcohq[mm2czDJSm4u|rNvaX7keYNm\CCFQ1yyNkBxem:mdXP0bY9vKGyndnXsdy=> MoTMNlU5OzR|NUO=
HaCaT  MUXGeY5kfGmxbjDBd5NigQ>? MWW1JOK2VQ>? M{LnXVI1KGh? MWLpcohq[mm2czDJSm4u|rFvaX7keYNm\CCFQ1yyNkBxem:mdXP0bY9vKGyndnXsdy=> NIPEUWwzPTh|NEO1Ny=>
HPAEpiCs  MVjGeY5kfGmxbjDBd5NigQ>? M2L3SlEwOy9zMDFOwG0> M3fPUVEhcA>? MmGwdoVlfWOnczDTNXAucW6mdXPl[EBKS0GPLUGgdJJwfGWrbjDhcoQhdVKQQTDlfJBz\XO|aX;uJIFv\CCycn;tc5RmeiCjY4Tpeol1gQ>? NVPIXGd5OjV5M{S5NFA>
HPAEpiCs MYHGeY5kfGmxbjDBd5NigQ>? MnvrNU8{NzFyIN88US=> MmnTNUBp M2rQWIlvcGmkaYTzJHMyWC2|dHnteYxifGWmIFHreEBxcG:|cHjvdplt[XSrb36gJOKh NGLEO3gzPTd|NEmwNC=>
HPAEpiCs M2TqdGZ2dmO2aX;uJGF{e2G7 MmnDNU8{NzFyIN88US=> NXe2R3JSOSCq NX30TGFkcW6qaXLpeJMhWzGSIITpcYUu\GWyZX7k[Y51dHlic4TpcZVt[XSnZDDjMWp2diCyaH;zdIhwenmuYYTpc44> MWmyOVc{PDlyMB?=
K562 MoOxSpVv[3Srb36gRZN{[Xl? NITGW2wyOMLizszN MV:xxsBp Mn3pSG1UVw>? Ml75bY5pcWKrdIOgdZVqdmGlcnnu[U1qdmS3Y3XkJJA{QCCPQWDLJJBpd3OyaH;yfYxifGmxbh?= NFjZU4EzPTZ6NEC0Ny=>
PANC-1 M2LQV2Z2dmO2aX;uJGF{e2G7 M1rxOVExKM7:TR?= NFrCcosyKGh? MXXlcohidmOnczD0bIUh[XW2b4DoZYdq[yCnZn\lZ5TDqA>? NGPPdYgzPTZ|MkKyNi=>
BxPC-3 M1HGZmZ2dmO2aX;uJGF{e2G7 NHnx[2wyOCEQvF2= MYmxJIg> MmjH[Y5p[W6lZYOgeIhmKGG3dH;wbIFocWNiZX\m[YN1yqB? MXSyOVY{OjJ{Mh?=
K562  MVLGeY5kfGmxbjDBd5NigQ>? M1T3SVAvOjVvMTFOwG0> MmXpNlQhcA>? MWjzeZBxemW|c3XzJJJme3[ncnH0do9tNWmwZIXj[YQhUDKDWDDwbI9{eGixconsZZRqd25? M4nXb|I2PjF7M{my
THP-1 MYjGeY5kfGmxbjDBd5NigQ>? MojGOUDDvU1? Ml[3NkBp MUPzbYdvcW[rY3HueIx6KGG2dHXueYF1\XNic3XjdoV1cW:wIH;mJGlNNTIQsTDpcoR2[2WmIHL5JFI4V0iFaH;sJJBtfXNiRmPMMVHDqA>? MUeyOVU6QDZ4MR?=
WB M{X4SmZ2dmO2aX;uJGF{e2G7 M2PCRVIx6oDLzszNxsA> MnvlN|DjiImvaX6= MlzE[IVkemWjc3XzJJRp\SCOUGOtJI9zKEyWQT3pcoR2[2WmIFnMMVYh[W6mIGTOSk3PucLicILv[JVkfGmxbh?= MnH2NlU2OzB4OEK=
RAW 264.7 M2TNPWZ2dmO2aX;uJGF{e2G7 M2i0V|ExyqEQvF2= MVmzNQKBkW2rbh?= NF\aZ3BqdmS3Y3XzJINp[XKjY4Tldol{fGmlII\hZ5VwdGG2aX;uJI9nKE:Fc9Mg NFjiRXMzPTR4MUO5PS=>
RAW 264.7 M4rBbGZ2dmO2aX;uJGF{e2G7 NHjxZowyOMLizszN M3O4VFMx6oDLbXnu M1e1[YF1fGWwdXH0[ZMhfGinIHXm[oVkfHNib3[gU3BIKG:wIH;zeIVw[2yjc4SgdoV1emGldHnvci=> MoPJNlU1PjF|OUm=
HaCaT  NIHie5FHfW6ldHnvckBCe3OjeR?= Mme4OFDDqM7:TR?= MWmzMVI1KGh? M{j4NWROW09? MWLy[YR2[2W|IITo[UBi[2O3bYXsZZRqd25ib3[gXm8uOQ>? NHnDb2YzPTR|NUS4OS=>
H9c2 MUnGeY5kfGmxbjDBd5NigQ>? NEO4VJQ2OMLizszNxsA> NX[0SWVrOTJiaB?= M3XHVZJm\HWlZYOgUGRJKHKnbHXhd4Uh[W6mIF3NVEBtd3O| MlzBNlUzPDV6MUi=
HSCs M{D3RmFxd3C2b4Ppd{BCe3OjeR?= NGLVTpEzPSEQvF2= MnnENlTDqGh? MYTzbYdvcW[rY3HueIx6KGG2dHXueYF1\XNiVFetbY5lfWOnZDDhZ5RqfmG2ZXSgTHNEeyCjcH;weI9{cXN? MmDpNlQ6PjF7NUC=
THP-1 NY\GfGNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUG3NkBp NXnQUpFnTE2VTx?= MXPJR|UxRTRwN988US=> NWTEWI1mOjR6MUWwPFc>
MDDCs M4LYcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LMVVczKGh? MW\EUXNQ M2jVRWlEPTB{LkhOwG0> M2DYZlI1QDF3MEi3
MDDCs NITlN3FHfW6ldHnvckBCe3OjeR?= MYewMVE2KM7:TR?= MlnZOFghcA>? NYDOT2NiTE2VTx?= M3e4XpN2eHC{ZYPz[ZMhUU[QLd8xJIFv\CCLUD2xNEBxem:mdXP0bY9vyqB? NWDGTZYyOjR6MUWwPFc>
MDDCs NVLufnE2TnWwY4Tpc44hSXO|YYm= NGG2TnQxNTF3IN88US=> NYjZWpFQPDhiaB?= MVLEUXNQ MmnLbY5pcWKrdIOgUWlRNTGjLDDNTXAuOWJiYX7kJHJCVlSHUzDwdo9lfWO2aX;u NVi4OWNpOjR6MUWwPFc>
MDDCs MWfGeY5kfGmxbjDBd5NigQ>? NXn5PXlpOTBizszN NUnENHRtOy53IHi= NXLHdJpnTE2VTx?= MWficI9kc3NiRVLPWkBIWCxiYoX0JI5wfCCYU2[gS{Bu\WSrYYTl[EBmdnS{eTDpcpRwKGi3bXHuJG1FTEO| NWXifZBlOjR6MUWwPFc>
macrophages NVvmepNtTnWwY4Tpc44hSXO|YYm= M2nBVFHjiIoQvF2= M172VlQvPeLCiXi= NGX3bYVkd22ybHX0[Yx6KGmwaHnibZR{KE2WLVnJTU1qdmS3Y3XkJIFkfGm4YYTpc44hd2ZiTl[t{tpD M1jaUlI1QDB6NkOz
PDL  MXfGeY5kfGmxbjDBd5NigQ>? MoT0NlDDqM7:TdMg M4rYVlMxKG2rbh?= NHT6WHdFVVOR NHnLfZF{cWewaX\pZ4FvfGy7IHnubIljcXS|IITo[UB1\W6|aXzlJIZwemOnLX3l[IlifGWmIFLNVE0zKGW6cILld5Nqd25? NIP6SZQzPDV4MUC4NS=>
AGS M3zXO2Z2dmO2aX;uJGF{e2G7 MmLZOUDPxE1? MkPFN|AhdWmw M2jX[JN2eHC{ZYPz[ZPDqDFvaX7keYNm\CClYYPwZZNmNThiYX7kJINie3Cjc3WtN{Bi[3SrdnH0bY9v MoLpNlQ2PDd6N{i=
H520 MmrBSpVv[3Srb36gRZN{[Xl? NXXPVG86OTEEoNM1US=> Mn;kNUBp NIr2UIRFVVOR MXTk[YNz\WG|ZYOgeIhmKHCnbXX0doV5\WRvaX7keYNm\CCPU1iyJI1TVkFiYX7kJJBzd3SnaX6gcIV3\Wy| MU[yOFU{ODR5NR?=
H1703 MYTGeY5kfGmxbjDBd5NigQ>? MX6xNOKhyrWP MkjJNUBp NWi3[VZvTE2VTx?= NY\NT|FF\GWlcnXhd4V{KHSqZTDw[Y1mfHKneHXkMYlv\HWlZXSgUXNJOiCvUl7BJIFv\CCycn;0[YlvKGyndnXsdy=> NVexVXBZOjR3M{C0O|U>
H520 MoPVSpVv[3Srb36gRZN{[Xl? Mn;sNVDDqML3TR?= M{X2XFEzKGh? MUfEUXNQ NUHxRpdWcW6qaXLpeJMheGWvZYTy[Zhm\C2nbHnjbZRm\CCPU1iyJJBzd3SnaX6gd5Ri[mmuaYT5 NYLTWZNXOjR3M{C0O|U>
H1703 MUfGeY5kfGmxbjDBd5NigQ>? NEXVbJMyOMLiwsXN NWXrUXJuOTJiaB?= NH2zfldFVVOR NYjOdpY{cW6qaXLpeJMheGWvZYTy[Zhm\C2nbHnjbZRm\CCPU1iyJJBzd3SnaX6gd5Ri[mmuaYT5 NYTBeGVCOjR3M{C0O|U>
H520 NX;LZ45rTnWwY4Tpc44hSXO|YYm= M1Xx[FExyqEEtV2= MXe2JIg> NUHOeZJbTE2VTx?= M2HreZNq\26rZnnjZY51dHliaX7jdoVie2W|IITo[UBt\X[nbIOgc4YhfWKrcYXpeIlvNWOxbnr1[4F1\WRiTWPINkBqdiCyZX3leJJmgGWmLYTy[YF1\WUEoHPlcIwhdGmwZR?= NHHPSpUzPDV|MES3OS=>
H1703 MkHBSpVv[3Srb36gRZN{[Xl? MoTPNVDDqML3TR?= NFjwSXU3KGh? M3\uO2ROW09? MX7zbYdvcW[rY3HueIx6KGmwY4LlZZNmeyC2aHWgcIV3\Wy|IH;mJJVjcXG3aYTpck1kd26sdXfheIVlKE2VSEKgbY4heGWvZYTy[Zhm\C22cnXheIVlyqClZXzsJIxqdmV? NXPaOXVVOjR3M{C0O|U>
MC3T3-E1 MX;GeY5kfGmxbjDBd5NigQ>? NF;nRZIxNjNxMz:zNEDPxE1? MkjBNUBp MUfheJRmdnWjdHXzJHRPTi4QsT3pcoR2[2WmIF3NVE06KGW6cILld5Nqd25iaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= MWKyOFUxOjZ7Nh?=
MC3T3-E1 M4fxcWZ2dmO2aX;uJGF{e2G7 MkP5N|Ah|ryP NULMeVloOSCq MU\heJRmdnWjdHXzJHRPTi4QsT3zeIlufWyjdHXkJJA{QCCPQWDLJJBpd3OyaH;yfYxifGmxbh?= M2P1UFI1PTB{Nkm2
HUVECs  MVzGeY5kfGmxbjDBd5NigQ>? MWixNOKhyrWP NUPZTFM4OSCq M37RbolvcGmkaYTzJHRPTi4QsT3pcoR2[2WmIFPYR2wyKHC{b3T1Z5Rqd25? NEnYWHEzPDR6N{m2OC=>
AGS  M3jYZWZ2dmO2aX;uJGF{e2G7 NI\LTWcyOMLiwsXN NGPSRnA{OMLibXnu NXzaUXlscW6qaXLpeJMhUUxvMd8yMYlv\HWlZXSgZYN1cX[jdHnvckBw\iCyM{i= MYiyOFQ4QTZ6MR?=
MKN-45 MoHZSpVv[3Srb36gRZN{[Xl? NXnD[YY4OTEEoNM1US=> NWjIXG1POzEEoH3pci=> MVHpcohq[mm2czDJUE0y|rJvaX7keYNm\CCjY4TpeoF1cW:wIH;mJJA{QA>? MmHtNlQ1Pzl4OEG=
AGS  NG\4dlNHfW6ldHnvckBCe3OjeR?= NVnC[3ZtOTEEoNM1US=> M1jpb|MxyqCvaX6= NFy2cmdifHSnboXheIV{KEmOLUJOtk1qdmS3Y3XkJGdCKGOnbHygcYloemG2aX;uJIFv\CCrbo\hd4lwdg>? NVr5b5NCOjR2N{m2PFE>
MKN-45 MXjGeY5kfGmxbjDBd5NigQ>? NFPUZVgyOMLiwsXN NI[0SGU{OMLibXnu NHfadY9ifHSnboXheIV{KEmOLUJOtk1qdmS3Y3XkJGdCKGOnbHygcYloemG2aX;uJIFv\CCrbo\hd4lwdg>? M2P3[FI1PDd7Nkix
AGS  NEWxZmpHfW6ldHnvckBCe3OjeR?= NVLQV4g1OTEEoNM1US=> NELU[3Y{OMLibXnu M2XjfZNq\26rZnnjZY51dHliZHXjdoVie2W|IFnsMVHPui2rbnT1Z4VlKE2PUEKgZY5lKE2PUEmgcXJPSSCneIDy[ZN{cW:w MVKyOFQ4QTZ6MR?=
MKN-45 NUjCSWhPTnWwY4Tpc44hSXO|YYm= M3vCSFExyqEEtV2= NEfQeHc{OMLibXnu MV3zbYdvcW[rY3HueIx6KGSnY4LlZZNmeyCLbD2x{tIucW6mdXPl[EBOVVB{IHHu[EBOVVB7IH3SUmEh\XiycnXzd4lwdg>? NGHTeoszPDR5OU[4NS=>
DCs MUHGeY5kfGmxbjDBd5NigQ>? NIfEOYozOMLizszN Mo[yNeKhcA>? MWHk[YNz\WG|ZYOgTWwuOTJicILv[JVkfGmxbh?= MkL5NlQ1OzR4M{[=
HUVEC  M2jPeWZ2dmO2aX;uJGF{e2G7 MnjONlAh|ryvwrC= NWL0PYtGPSCq NVPLeJVJTE2VTx?= MorWdoVlfWOnczDjfZRwc2mwZTDlfJBz\XO|aX;uJIxmfmWuczDpckBiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JI1idm6nch?= MkLwNlQyQDlyNkK=
A 549 MWjGeY5kfGmxbjDBd5NigQ>? MXW1NEDPxE1? MUGxJIg> M2\4WYRm[3KnYYPld{B1cGVibHX2[Ywhd2ZiSVytPOKh M2LJN|I1OTd7Nki4
H520  MnLFSpVv[3Srb36gRZN{[Xl? M3vmNlUwOTBizszN MUixJIg> NWXkVnlqTE2VTx?= M4fuOIRm[3KnYYPld{BOW0h{IIDyc5RmcW5iYYOge4VtdCCjczDtVm5CKGyndnXsd{BqdiCpZX\peIlvcWJvZYjwc5Nm\CClZXzs Mk\tNlQyOzh7MEO=
H1703  NWiyc4hpTnWwY4Tpc44hSXO|YYm= MUC1M|ExKM7:TR?= M4jFOVEhcA>? Mm\lSG1UVw>? NVzTN2Jn\GWlcnXhd4V{KE2VSEKgdJJwfGWrbjDhd{B4\WyuIHHzJI1TVkFibHX2[Yx{KGmwIHfl[ol1cW6rYj3lfJBwe2WmIHPlcIw> MUWyOFE{QDlyMx?=
H520  Mn[zSpVv[3Srb36gRZN{[Xl? NVnMWXR5OTEEoNM1US=> NVXV[2JrOTJiaB?= NULrUXYyTE2VTx?= M1ixUoRm[3KnYYPld{BOW0h{IH3SUmEh[W6mIIDyc5RmcW5ic4ThZoltcXS7IHnuJIdm\mm2aX7pZk11emWjdHXkJG5US0yFIHPlcIx{ NXrt[okyOjRzM{i5NFM>
H1703  NIjURYtHfW6ldHnvckBCe3OjeR?= MkXDNVDDqML3TR?= NWDDNlBnOTJiaB?= MoXmSG1UVw>? Mmex[IVkemWjc3XzJG1UUDJibWLORUBidmRicILveIVqdiC|dHHibYxqfHliaX6g[4VncXSrbnniMZRz\WG2ZXSgUnNEVENiY3XscJM> NVTEXm9bOjRzM{i5NFM>
MCF-7  M2TVXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWqxNOKh|ryP NWfGXoxmOjUEoHi= MofhbY5pcWKrdIOgeIhmKEOUMUC4MYlv\HWlZXSgZ4VtdCCmZXH0bC=> Mo[4NlQyOjh6NUO=
HPAEpiCs MYTGeY5kfGmxbjDBd5NigQ>? NGTTXZkxNjFxMT:xNEDPxE1? NV3kTpZxOSCq M4H2VolvcGmkaYTzJHRPTi4QsT3pcoR2[2WmIHPQUGEzyqCycn;0[YlvKGGwZDDtVm5CKGW6cILld5Nqd25? NW\mV2lrOjRyNkmxOVg>
podocytes MoXjSpVv[3Srb36gRZN{[Xl? MmH1NVDDqM7:TR?= M1jwbFEhcA>? M1i2N4lvcGmkaYTzJHRITs7{MT3pcoR2[2WmIHHjeIl3[XSrb36gc4YheDN6TVHQT{BidmRiRYLrNU8zyqB? MWiyOFA{PjJzMh?=
MCF-7 MULGeY5kfGmxbjDBd5NigQ>? NH7VNnEyOMLizszN NU\sUpNPOSCq MlnOSG1UVw>? NWLTZYgxemWmdXPld{B1cGViV1GtbY5lfWOnZDDwbI9{eGixconsZZRm\CCyM{igUWFRUw>? M4jH[|I1ODF7MEmw
MCF-7 NFrVWodHfW6ldHnvckBCe3OjeR?= NUTqR|ZLOTEEoN88US=> Mn7zNlQhcA>? MkfXSG1UVw>? MXrpcoNz\WG|ZYOgeIhmKFeDLXnu[JVk\WRiYYDvdJRwe2m| NIizPHczPDBzOUC5NC=>
HAPI M1XtdGZ2dmO2aX;uJGF{e2G7 Mn3ONVAwOjBxNEFCpO69VQ>? MnvyNUBp Mkj0bY5pcWKrdIOgWGNFTC2rbnT1Z4VlKHB|OD;KUmshVUGSSzDwbI9{eGixconsZZRqd25? MX[yN|k3QTF{MB?=
HAPI NXf3[WdWTnWwY4Tpc44hSXO|YYm= M3K0NlIxyqEQvF5CpC=> MnvHNUBp NYW3OWI6TE2VTx?= MWXheJRmdnWjdHXzJHRETERvaX7keYNm\CCjY4TpeoF1cW:wIH;mJIlPV1NiYX7kJJBzd2S3Y4Tpc44> NWPVS2xTOjN7NkmxNlA>
HepG2 NIjGVXJHfW6ldHnvckBCe3OjeR?= NHTiPHE{PTBibl2= NELHSXkzPCCq MoWwbY5pcWKrdIOgeIhmKGSnZ4XlcIlvNWmwZIXj[YQh[WO2aY\heIlwdiCxZjDwN|hOSVCN M1TlflI{QTN|MUm4
AGS  NUe4VFBKTnWwY4Tpc44hSXO|YYm= MVKxNOKh|ryP Ml\EN|AhdWmw MXzpcohq[mm2czDjZZNx[XOnLUOgZYN1cX[jdHnvckBidmRiaX7obYJqfGmxbjDv[kBGWkt? NYO5[mlNOjN6NUC5PVQ>
HepG2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTvNE02OCEQvF2= MmfEOFghcA>? Mnj2bY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MYOyN|gxPzVyOB?=
BEL7404 NWHUVZV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXOwMVUxKM7:TR?= Mn7YOFghcA>? M2iy[IlvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy MUKyN|gxPzVyOB?=
HL7702 M{PjSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnLdmIxNTVyIN88US=> NWHxdolmPDhiaB?= NETJSlVqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NV3xe4s4OjN6MEe1NFg>
HepG2 MnTESpVv[3Srb36gRZN{[Xl? M1HB[|AuPTBizszN MmfvNlQhcA>? M3fUU4lvcGmkaYTzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZicEO4JIRwf26|dILlZY0heHKxdHXpcpMhVUGSS1HQT|ItKEGWRkKsJG1UUzFiYX7kJGhUWDJ5IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NU\mW2FJOjN6MEe1NFg>
BEAS-2B MlzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7uNVAh|ryP NFfzVVg{OCCvaX6= NYnyUnQ5emW4ZYLz[ZMhfGinIHTlZ5Jm[XOnIH;mJINmdGxidnnhZoltcXS7IHnu[JVk\WRiYomgTGNK MmjLNlM4QDRyM{S=
BEAS-2B NHPneFREgXSxdH;4bZR6KEG|c3H5 NX7Ye3NIOTBizszN MojTN|AhdWmw M4Wwd4lvcGmkaYTl[EB1cGViaX7jdoVie2ViaX6gUGRJKGGwZDDJUE05KGW6cILld5Nqd25? Ml3ZNlM4QDRyM{S=
BEAS-2B NFXNVG9HfW6ldHnvckBCe3OjeR?= MXyxNEDPxE1? MknpN|AhdWmw NEnseJll\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDjZZNx[XOnLUOsJGJi\CCjbnSg[oF{ NYTLOFhpOjN5OESwN|Q>
H9c2  NX7a[HplTnWwY4Tpc44hSXO|YYm= NILxNooxNjBzL{CuNU8yKM7:TR?= M{nEW|EhcA>? NVzWdWM5[XS2ZX71ZZRmeyCWTl[t{tEucW6mdXPl[EBOVVBvOTDlfJBz\XO|aX;uMEBuWk6DIHzleoVteyxiYX7kJJBzd22xdHXyJIFkfGm4aYT5 Mn;ENlM4PzR{NUK=
H9c2  M4DTNGZ2dmO2aX;uJGF{e2G7 MUexJO69VQ>? MXixJIg> NWL1b3J1emWmdXPld{BVVkZvzsGg[Ilz\WO2bImgd5RqdXWuYYTl[EBxOzhiTVHQT{BxcG:|cHjvdplt[XSrb36= NX\5dYtNOjN5N{SyOVI>
U937 NHfvVZpHfW6ldHnvckBCe3OjeR?= M1vSZlExyqEQvF5CpC=> NULENVRVOSCq NYrhNmty[WK{b3fheIV{KHSqZTDjZYZn\WmwZTDl[oZm[3Rib36gUWtRNTFiYX7kJHBROkGlzsGgcXJPSSC2cnHud4NzcXC2aX;uZYwhdGW4ZXzz Mn7sNlM4ODd|OEe=
U937 M4SySWZ2dmO2aX;uJGF{e2G7 NGnZbHgyOMLizszNxsA> Mn3XNUBp MkfjZYJzd2ejdHXzJINi\m[naX7lMYlv\HWlZXSgUWtRNTFiZH;3ck1z\We3bHH0bY9vKGGwZDDQVFJC[87zIIXwMZJm\3WuYYTpc44> NWrEUJVmOjN5MEezPFc>
U937 MYDGeY5kfGmxbjDBd5NigQ>? NYT3OIU1OTEEoN88UeKh MoTTNUBp MULzeZBxemW|c3XzJIMuUnWwIHHu[EBEWkWEIIDoc5NxcG:{eXzheIlwdiCrbjDjZYZn\WmwZT30doVifGWmIHPlcIx{yqB? M4W1flI{PzB5M{i3
A549 NUW2eppzTnWwY4Tpc44hSXO|YYm= NHSzPZQxNjNxMz:zNEDPxE1? MmrwNUBp NGfr[ZB{cWewaX\pZ4FvfGy7IHH0eIVvfWG2ZYOgRXRR|rOVLX3l[IlifGWmIFPPXE0zKHC{b4TlbY4h[W6mIH3SUmEh\XiycnXzd4lwdiCjbnSgdJJwdW:2ZYKgZYN1cX[rdIpCpC=> NIe3N3kzOzZ6ME[3OC=>
A549 NF7jUWhHfW6ldHnvckBCe3OjeR?= NXjS[nc2OTEEoN88UeKh NFXKXGwxNTNyIH3pci=> Mn3vbY5pcWKrdIOgRXRR|rOVIHnu[JVk\WRicESyM5A1PCCPQWDLJIFv\CCyM{igUWFRUyCyaH;zdIhwenmuYYTpc44> MXiyN|Y5ODZ5NB?=
A549 MUDGeY5kfGmxbjDBd5NigQ>? NYH2VJZEOTEEoN88UeKh NF3McG4yKGh? M2fQeolvcGmkaYTzJGFVWM7|UzDpcoR2[2WmIF7GMe67SiCyNkWgd5VjfW6rdDDwbI9{eGixconsZZRqd25iYX7kJG5HNc78QjDwdo9ud3SncjDhZ5Rqfmm2eR?= NYqyNHpvOjN4OEC2O|Q>
A549 Mnr1SpVv[3Srb36gRZN{[Xl? NXviZnVQOTEEoN88UeKh Mor1NUBp MXPy[YR2[2W|IFHUVO6{Wy2|dHnteYxifGWmIHPQUGEzKHCqb4PwbI9zgWyjdHnvcuKh M3nwXFI{PjhyNke0
A549 NFLOV2FHfW6ldHnvckBCe3OjeR?= M2TsN|ExyqEQvF5CpC=> MVexJIg> M4r1XZJm\HWlZYOgRXRR|rOVLXXubIFv[2WmIHXufplu[XSrYzDhZ5Rqfmm2eTDv[kBkWEyDMtMg MlLCNlM3QDB4N{S=
PC12 NH;3d4dHfW6ldHnvckBCe3OjeR?= NE\rUoMyOC9{MD:0NEDPxE1? NVHGPJNVOcLiaB?= NYDtbIVOcW6qaXLpeJMhUk6NIHHu[EBxOzh? MViyN|U5PDN3Nx?=
HK-2 M1jCcGFxd3C2b4Ppd{BCe3OjeR?= NHu3WZYzOMLizszN M3;oNFI1KGh? MYHpcohq[mm2czDFVmsh[W6mIICzPG1CWEt? Ml;BNlM2PDNzNUG=
H9c2 NXHHOWc3TnWwY4Tpc44hSXO|YYm= NEjZSHoyyqEQvF2= MYSxJIg> NYjtNY92emWmdXPld{BVVkZvzsGtbY5lfWOnZDDNUXAuQSCvUl7BJIxmfmWuczDhcoQheHKxbX;0[ZIh[WO2aY\peJk> MknHNlM{PTN4OUm=
H9c2 NEDGVplHfW6ldHnvckBCe3OjeR?= NXvofGxYOcLizszN NYTyUGNNOSCq M{n2cpJm\HWlZYOgWG5HNc7zLXXubIFv[2WmIFHQMVEheHKxbX;0[ZIh[WO2aY\peJk> NGOzOmgzOzN3M{[5PS=>
H1650  MVPGeY5kfGmxbjDBd5NigQ>? M{\L[|ExyqEQvF5CpC=> MVexJIg> NWruV2pZTE2VTx?= M1vROIRm[3KnYYPld{Bjd3SqIIDyc5RmcW5iYX7kJI1TVkFibHX2[Yx{KG:oIFXSR2MyKGmwIIDhZ4xqfGG6ZXyt[Zhxd3OnZNMgZ4VtdHN? NGPPeG8zOzJ{OE[5Oi=>
H1703 NVvJWmJXTnWwY4Tpc44hSXO|YYm= MXqxNOKh|ryPwrC= NXz3dW9tOSCq MnHBSG1UVw>? MoTN[IVkemWjc3XzJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcJMhd2ZiRWLDR|EhcW5icHHjcIl1[XinbD3lfJBwe2WmwrDj[Yxtew>? M13y[|I{OjJ6Nkm2
H1650  M1;STGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzZZmhWOTEEoN88UeKh MlXFNUBp NITMOmlFVVOR NG[xfHpmdmijbnPld{Bx[WOuaYThfIVtNWmwZIXj[YQh[3m2b4TvfIlkcXS7 NVXUb|ZzOjN{Mki2PVY>
H1703 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrINVRPOTEEoN88UeKh NHXFS2syKGh? M3qw[GROW09? M{PIT4VvcGGwY3XzJJBi[2yrdHH4[YwucW6mdXPl[EBkgXSxdH;4bYNqfHl? NUS4fWZYOjN{Mki2PVY>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
mTOR / p-S6K / S6K / p-S6 / p-AKT / p-MK2; 

PubMed: 26844273     


CRC cells were treated with 10 μM SB202190 for 2 h and analyzed for mTOR signaling and on-target inhibition of p38 by immunoblot. 

pJNK1 / pJNK2 / JNK1 / JNK2 ; 

PubMed: 18222647     


A549 cells were treated with DMSO control or with 10 µM of SB202190 for 0.5, 1, 2, 3, 4, or 6 hours, and pJNK and unphosphorylated JNK were detected as described. 

26844273 18222647
Immunofluorescence
p-p38 / MMP9; 

PubMed: 24479681     


Immunocytochemical staining and confocal microscopy confirmed that IL-1β increased activation of p38 (red), and MMP2 and MMP9 (green) expression in MKN-45 GA cells; these effects were blocked by p38 siRNA or the p38 inhibitor SB202190.

24479681
Growth inhibition assay
Cell viability ; 

PubMed: 26844273     


Top panel: CRC cells were treated with various concentrations of SB202190 for 48 h. Lower panel: CRC cells were treated with SB202190 at 10 μM for different times. Cell growth was measured by SRB assay (means ± s.d. in triplet, n = 3 in triplet).

26844273
In vivo Inhibiting p38 by administration of SB 202190 inhibits PV IgG-induced blister formation in the passive transfer mouse model. [5] In the endotoxin model of sepsis, SB 202190 treatment produces a statistically significant survival benefit compared with control. [8]

Protocol

Kinase Assay:

[1]

- Collapse

In vitro kinase assays:

The p38α and p38β are assayed in 25 mM Tris-HCl, pH 7.5, containing 0.1 mM EGTA, with myelin basic protein (0.33 mg/mL) as substrate. Assays are performed either manually for 10 minutes at 30 °C in 50 μL incubations using [γ-33P]ATP, or with a Biomek 2000 Laboratory Automation Workstation in a 96-well format for 40 minutes at ambient temperature in 25 μL incubations using [γ-33P]ATP. The concentrations of ATP and magnesium acetate are 0.1 mM and 10 mM respectively. All assays are initiated with MgATP. Manual assays are terminated by spotting aliquots of incubation on to phosphocellulose paper, followed by immersion in 50 mM phosphoric acid. Robotic assays are terminated by the addition of 5 μL of 0.5 M phosphoric acid before spotting aliquots on to P30 filter mats. All papers are then washed four times in 50 mM phosphoric acid to remove ATP, once in acetone (manual incubations) or methanol (robotic incubations), and then dried and counted for radioactivity.
Cell Research:

[2]

- Collapse
  • Cell lines: Jurkat, and HeLa
  • Concentrations: Dissolved in DMSO, final concentrations ~50 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are serum-starved and then treated with different concentration of SB 202190 for 24 hours. Cell viability is assayed by either trypan blue exclusion or propidium iodide exclusion followed by flow cytometry analysis. The apoptotic nuclei are visualized by H33258 staining.


    (Only for Reference)
Animal Research:

[5]

- Collapse
  • Animal Models: C57BL/6J mice injected i.d. with a sterile solution of either control IgG or PV IgG
  • Dosages: 12.5 μg
  • Administration: Administered via i.d.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 66 mg/mL (199.19 mM)
Ethanol 12 mg/mL (36.21 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
1% DMSO+30% polyethylene glycol+1% Tween 80
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 331.34
Formula

C20H14N3OF

CAS No. 152121-30-7
Storage powder
in solvent
Synonyms N/A
Smiles OC1=CC=C(C=C1)C2=NC(=C([NH]2)C3=CC=NC=C3)C4=CC=C(F)C=C4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

Related p38 MAPK Products

Tags: buy SB202190|SB202190 ic50|SB202190 price|SB202190 cost|SB202190 solubility dmso|SB202190 purchase|SB202190 manufacturer|SB202190 research buy|SB202190 order|SB202190 mouse|SB202190 chemical structure|SB202190 mw|SB202190 molecular weight|SB202190 datasheet|SB202190 supplier|SB202190 in vitro|SB202190 cell line|SB202190 concentration|SB202190 nmr|SB202190 in vivo|SB202190 clinical trial|SB202190 inhibitor|SB202190 MAPK inhibitor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID